RSR13, a potential athletic performance enhancement agent: detection in urine by gas chromatography/mass spectrometry

Abstract

RSR13 (2‐[4‐[[(3,5‐dimethylanilino)carbonyl]methyl]phenoxyl]‐2‐methylpropionic acid) is a synthetic allosteric modifier of hemoglobin that is currently in a phase III clinical trial as a radio‐enhancing agent. RSR13 has been shown to increase maximum oxygen uptake (VO_2max) in a canine skeletal model, which makes it a potential performance‐enhancing agent for endurance athletes, since VO_2max is an index of aerobic capacity. In this study we present a method for the detection of RSR13‐bis‐TMS in human urine by gas chromatography/electron impact ionization mass spectrometry (GC/EI‐MS) suitable for doping control laboratories. The presence of RSR13 is detected by monitoring the ions m/z 485 ([M]^+·) and 470 ([M − CH₃]⁺). The limit of detection (LOD) is less than 2 ng/mL in urine. Urine samples collected from clinical trial subjects immediately prior to receiving an infusion of RSR13 showed no evidence of RSR13, whereas post‐infusion urine samples contained up to 1181 µg/mL. A urine sample collected 36 h after administration of a small dose (10 mg/kg) and diluted 100‐fold showed a signal 80 times higher than the LOD. Urine samples obtained from 100 randomly selected athletes in our routine testing program did not show any traces of RSR13. Sport authorities may wish to add RSR13 to the list of prohibited substances. Copyright © 2001 John Wiley & Sons, Ltd.